pegylated liposome simoctocog alfa (SelectAte) / Ascension Healthcare - LARVOL DELTA

Ascension Healthcare plc: Business Update (GlobeNewswire) - P2, N=20; NCT04592692; Sponsor: Ascension Healthcare Development Limited; "Ascension Healthcare plc...today provides an update on its haemophilia clinical programmes and consumer healthcare business....SelectAte....The inhibitor arm of the study is almost complete with 9 patients out of 10 processed and the non-inhibitor arm comprising 10 patients has completed. Positive results have been observed to date across both arms indicating the potential for a safe FVIII replacement treatment for inhibitor patients and an extension of dosing interval when compared to existing FVIII replacement therapies. Ascension’s ‘XLR8’ (formerly ‘ChapAte’)....Positive results were obtained from this study, also indicating the potential for an extended dosing interval, without compromising haemostatic cover, in patients currently receiving prophylactic FVIII standard of care. Final study reports will be available for both SelectAte and XLR8 in Q1 2022."

Enrollment status • P2 data • Genetic Disorders • Hemophilia

Business update and change of name from Pro Bono Bio (GlobeNewswire) - "SelectAte Phase II clinical development programme initiated to evaluate the Company’s wholly-owned PEGLip technology in providing prophylactic Factor VIII (FVIII) treatment to haemophilia A (HA) patients with inhibitors to FVIII. Top-line results are expected during 2019….Two pre-clinical programmes initiated to prepare for Phase II clinical trials readiness, targeting (i) prophylactic FVIII treatment of HA patients subcutaneously (SubcutAte programme) and (ii) therapy for patients who, although not currently treated prophylactically, have moderate FVIII deficiency (ChapAte programme).”"

P2 data • Preclinical • Trial status